Use of an Anti-Interleukin-5 Antibody in the Hypereosinophilic Syndrome with Eosinophilic Dermatitis

New England Journal of Medicine

Volumn 349, Issue 24, 2003, Pages 2334-2339

  Plötz, Sabine Gisela ^a   Simon, Hans Uwe ^b   Darsow, Ulf ^a   Simon, Dagmar ^b   Vassina, Ekatherina ^b   Yousefi, Shida ^b   Hein, Rüdiger ^a   Smith, Tim ^c   Behrendt, Heidrun ^a   Ring, Johannes ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; DAPSONE; HUMANIZED INTERLEUKIN 5 ANTIBODY; IMATINIB; INTERLEUKIN 5 ANTIBODY; MEPOZULIMAB; PREDNISOLONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD EXAMINATION; CASE REPORT; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPEREOSINOPHILIC SYNDROME; IMMUNOFLUORESCENCE; LABORATORY TEST; PRIORITY JOURNAL; SKIN BIOPSY; WELLS SYNDROME;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CD4 LYMPHOCYTE COUNT; CYTOKINES; DERMATITIS; EOSINOPHILS; FEMALE; HUMANS; HYPEREOSINOPHILIC SYNDROME; INFUSIONS, INTRAVENOUS; INTERLEUKIN-5; LEUKOCYTE COUNT; MIDDLE AGED;

EID: 0346816643     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa031261     Document Type: Article

References (16)

1. Chusid MJ, Dale CD, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975;54:1-27.
2. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994;83:2759-79.
3. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesylate. Lancet 2002;359:1577-8.
4. Pardanani A, Reeder T, Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003;101:3391-7.
5. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-14.
6. Cogan E, Schandené L, Crusiaux A, Cochaux P, Velu T, Goldman M. Clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med 1994;330:535-8.
7. Simon HU, Plötz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999;341:1112-20.
8. de Lavareille A, Roufosse F, Schmid-Grendelmeier P, et al. High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome. J Allergy Clin Immunol 2002;110:476-9.
9. Simon HU, Plötz SG, Simon D, Dummer R, Blaser K. Clinical and immunological features of patients with interleukin-5-producing T cell clones and eosinophilia. Int Arch Allergy Immunol 2001;124:242-5.
10. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 2000;356:2144-8.
11. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003;167:199-204.
12. Kazmierowski JA, Chusid MJ, Parrillo JE, Fauci AS, Wolff SM. Dermatologic manifestations of the hypereosinophilic syndrome. Arch Dermatol 1978;114:531-5.
13. Plötz SG, Simon HU, Ring J. Skin manifestations in hypereosinophilic syndrome. (HES) - symptoms, therapy and pathophysiology. Allergologie 1999;21:489-96.
14. Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A 2003;100:7830-5.
15. Simon HU, Yousefi S, Schranz C, Schapowal A, Bachert C, Blaser K. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol 1997;158:3902-8.
16. Martes J, Yang M, Mahalingam S, et al. Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airway hyperreactivity in experimental asthma. J Exp Med 2002;195:1433-44.